Verastem Seeks Shareholder Approval for Significant Equity Plan Expansion, Potentially Diluting Existing Holders by 18.1%

summarizeSummary

Verastem, Inc. filed its definitive proxy statement for its Annual Meeting, seeking shareholder approval for a significant increase in shares available for its equity incentive and employee stock purchase plans, which could lead to 18.1% potential dilution.

check_boxKey Events

• Annual Meeting Scheduled

  The Annual Meeting of Stockholders will be held on Thursday, May 21, 2026, at 9:00 a.m. Eastern Time. The record date for voting is March 24, 2026.

• Proposed Expansion of 2021 Equity Incentive Plan

  Shareholders are asked to approve an amendment to the 2021 Equity Incentive Plan, increasing the number of shares available for issuance by 12,000,000. This alone represents approximately 12.0% potential dilution based on current outstanding shares and pre-funded warrants.

• Proposed Expansion of 2018 Employee Stock Purchase Plan

  Shareholders will vote on amending the 2018 Employee Stock Purchase Plan to increase the shares available for issuance by 5,000,000. This represents approximately 5.0% potential dilution.

• Total Potential Dilution from Equity Plans

  Including existing outstanding awards and the proposed increases, the total potential dilution from all equity incentive plans would be 18,155,480 shares, or 18.1% of the combined outstanding shares and pre-funded warrants.

auto_awesomeAnalysis

Verastem, Inc. has filed its definitive proxy statement (DEF 14A) for its upcoming Annual Meeting, outlining several key proposals for shareholder vote. The most significant items are the proposed amendments to the 2021 Equity Incentive Plan and the 2018 Employee Stock Purchase Plan, which collectively seek to authorize an additional 17,000,000 shares for issuance. This represents a substantial potential dilution of 18.1% when considering current outstanding shares and pre-funded warrants. While dilutive, the company emphasizes these equity incentives are critical for attracting and retaining high-quality talent, especially as it transitions to a fully integrated biopharmaceutical company with product revenue. Investors should monitor the outcome of these votes, as significant dilution could impact per-share value, even if strategically necessary for growth.